Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pain syndromes in haematological malignancies: an overview.
Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F, Trapè G, Morabito F. Niscola P, et al. Among authors: palombi f. Hematol J. 2004;5(4):293-303. doi: 10.1038/sj.thj.6200530. Hematol J. 2004. PMID: 15297845 Review.
[Stem cell mobilization after coronary artery bypass grafting].
Gaspardone A, De Fabritiis P, Scaffa R, Nardi P, Palombi F, Versaci F, Chiariello L. Gaspardone A, et al. Among authors: palombi f. Ital Heart J Suppl. 2004 Jan;5(1):23-8. Ital Heart J Suppl. 2004. PMID: 15253141 Italian.
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.
Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, Bendandi M, Martelli MP, Ascani S, Orcioni GF, Pileri SA, Mandelli F, Tura S. Zinzani PL, et al. Among authors: palombi f. Blood. 1999 Nov 15;94(10):3289-93. Blood. 1999. PMID: 10552937 Free article. Clinical Trial.
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. Zinzani PL, et al. Among authors: palombi f. Haematologica. 1999 Nov;84(11):996-1001. Haematologica. 1999. PMID: 10553159 Clinical Trial.
Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Arcese W, Mengarelli A; Rome Transplant Network. Renzi D, et al. Among authors: palombi f. Chemotherapy. 2017;62(1):58-61. doi: 10.1159/000448750. Epub 2016 Sep 10. Chemotherapy. 2017. PMID: 27618144 Free article.
Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F, Cerchiara E, Dessanti ML, Gumenyuk S, Franceschini L, Palombi F, Pisani F, Romano A, Spadea A, Pupo L, Annibali O, La Malfa A, Arcese W, Mengarelli A. Marchesi F, et al. Among authors: palombi f. Br J Haematol. 2015 Apr;169(2):293-6. doi: 10.1111/bjh.13199. Epub 2014 Nov 5. Br J Haematol. 2015. PMID: 25371286 Free article. No abstract available.
Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?
Marchesi F, Pimpinelli F, Di Domenico EG, Renzi D, Gallo MT, Regazzo G, Rizzo MG, Gumenyuk S, Toma L, Marino M, Cordone I, Cantonetti M, Liberati AM, Montanaro M, Ceribelli A, Prignano G, Palombi F, Romano A, Papa E, Pisani F, Spadea A, Arcese W, Ensoli F, Mengarelli A. Marchesi F, et al. Among authors: palombi f. Int J Mol Sci. 2019 Mar 19;20(6):1373. doi: 10.3390/ijms20061373. Int J Mol Sci. 2019. PMID: 30893777 Free PMC article.
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).
Rigacci L, Battistini R, Kovalchuk S, Zoli V, Puccini B, Evangelista A, Arcaini L, Flenghi L, Visco C, Mian M, Di Rocco A, Peracchio C, Gotti M, Tisi MC, Palombi F, Pozzi S, Gioia D, Viero P, Martelli M. Rigacci L, et al. Among authors: palombi f. Hematol Oncol. 2022 Oct;40(4):609-616. doi: 10.1002/hon.3028. Epub 2022 Jun 5. Hematol Oncol. 2022. PMID: 35612350 Clinical Trial.
Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG. Marchesi F, et al. Among authors: palombi f. J Exp Clin Cancer Res. 2018 May 2;37(1):95. doi: 10.1186/s13046-018-0768-5. J Exp Clin Cancer Res. 2018. PMID: 29716630 Free PMC article.
83 results